Preclinical Data Demonstrate That Deciphera Pharmaceuticals’ DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents...
Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson’s Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018 Evanston, Ill., March 15, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative...
by Jeff Fryer | Apr 24, 2018 Rallybio Completes $37.0M Series A Financing Rallybio Established by Industry Leaders with $37.0 Million in Series A Financing to Develop Transformative Therapies for Patients with Severe and Rare Diseases FARMINGTON, CT, April 25, 2018 –...
Harpoon Therapeutics Launches Immuno-Oncology Pipeline with Compelling Data from Lead Programs at the 2018 American Association for Cancer Research (AACR) Annual Meeting Preclinical Data Showcase New T Cell Engaging Platform (TriTAC™) and Lead Drugs, HPN424 and...
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform Financing round led by Nextech Invest. Proceeds to advance lead oncology programs into the clinic and broaden early-stage pipeline NEW HAVEN, CT, April 4, 2018 – Arvinas LLC, a...
Recent Comments